These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20067122)

  • 1. [Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
    Zhang SC; Zhang LL; Chen SW; Wu HY; Liu XK
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 40(6):1071-4. PubMed ID: 20067122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
    Lavigne JP; Bonnet R; Michaux-Charachon S; Jourdan J; Caillon J; Sotto A
    J Antimicrob Chemother; 2004 Apr; 53(4):616-9. PubMed ID: 14985275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
    Prakash SK; Arora V; Prashad R; Sharma VK
    J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae.
    König C; Blaser J
    J Antimicrob Chemother; 1995 Sep; 36(3):513-9. PubMed ID: 8830015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
    Sader HS; Rhomberg PR; Jones RN
    Antimicrob Agents Chemother; 2014; 58(4):2434-7. PubMed ID: 24449780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro demonstration of a true post-beta-lactamases inhibitor effect (PLIE) of clavulanic acid on Klebsiella pneumoniae and Haemophilus influenzae].
    Murbach V; Dhoyen N; Linger L; Monteil H; Jehl F
    Pathol Biol (Paris); 1999 May; 47(5):462-8. PubMed ID: 10418019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an
    VanScoy BD; Tenero D; Turner S; Livermore DM; McCauley J; Conde H; Bhavnani SM; Rubino CM; Ambrose PG
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
    Aldridge KE; Morice N; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postantibiotic and post-beta-lactamase inhibitor effect of carbapenems combined with EDTA against Pseudomonas aeruginosa strains producing VIM-metallo beta-lactamases.
    Bedenić B; Vranes J; Sviben M; Beader N; Kalenić S
    Chemotherapy; 2008; 54(3):188-93. PubMed ID: 18560225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.
    Babini GS; Danel F; Munro SD; Micklesen PA; Livermore DM
    J Antimicrob Chemother; 1998 Jan; 41(1):115-8. PubMed ID: 9511046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.